Skip to content

Inspection Record

Axogen Corporation — FDA 483 Findings

US FDAInspected 2025-04-29Published 2026-10-20 6 findingsEquipment and facilityEnvironmental monitoringLabeling and packagingDeviation, CAPA, and investigationLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Manufacturing building used in the manufacture ofAVANCE does not have the adequate controls to prevent contamination.

3Labeling and packaging

Procedures describing the warehousing ofAVANCE final product, printed product labels, and retain samples are not established.

4Deviation, CAPA, and investigation

Investigations into pest control deviations are deficient.

5Deviation, CAPA, and investigation

Deviation management is inadequate to demonstrate quality oversight ofthe manufacturing process.

6Laboratory and QC controls

Laboratory controls are not adequately established and do not include scientifically sound test procedures and sampling plans designed to assure that AVANCE drug product conform to appropriate standards of identity, strength, quality, and purity.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Axogen Corporation company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.